The artificial intelligence called Claude designed de novo protein-binding molecules, and based on a human expert prompt autonomously and successfully designed binders for 14 of the 15 targets tested. The designs were built and tested by Adaptyv Bio and Twist Bioscience, which could accelerate drug design.
AI-generated text
Claude artificial intelligence designed de novo protein binders for 14 of the 15 targets
The artificial intelligence called Claude designed de novo protein-binding molecules, and based on a human expert prompt autonomously and successfully designed binders for 14 of the 15 targets tested.
